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Structural insights into the potency 
of SK channel positive modulators
Young-Woo Nam1, Razan Orfali1, Tingting Liu2,3, Kunqian Yu2,3, Meng Cui4, Heike Wulff5 & 
Miao Zhang1
Small-conductance Ca2+-activated K+ (SK) channels play essential roles in the regulation of cellular 
excitability and have been implicated in neurological and cardiovascular diseases through both animal 
model studies and human genetic association studies. Over the past two decades, positive modulators 
of SK channels such as NS309 and 1-EBIO have been developed. Our previous structural studies 
have identified the binding pocket of 1-EBIO and NS309 that is located at the interface between the 
channel and calmodulin. In this study, we took advantage of four compounds with potencies varying 
over three orders of magnitude, including 1-EBIO, NS309, SKS-11 (6-bromo-5-methyl-1H-indole-
2,3-dione-3-oxime) and SKS-14 (7-fluoro-3-(hydroxyimino)indolin-2-one). A combination of x-ray 
crystallographic, computational and electrophysiological approaches was utilized to investigate 
the interactions between the positive modulators and their binding pocket. A strong trend exists 
between the interaction energy of the compounds within their binding site calculated from the crystal 
structures, and the potency of these compounds in potentiating the SK2 channel current determined by 
electrophysiological recordings. Our results further reveal that the difference in potency of the positive 
modulators in potentiating SK2 channel activity may be attributed primarily to specific electrostatic 
interactions between the modulators and their binding pocket.
Small-conductance Ca2+-activated K+ (SK) channels are encoded by the KCNN mammalian genes, includ-
ing KCNN1 for SK1 (KCa2.1), KCNN2 for SK2 (KCa2.2), KCNN3 for SK3 (KCa2.3) and KCNN4 for SK4 (IK or 
KCa3.1) channels1,2. SK channels resemble voltage-gated potassium channels in their overall tetrameric assem-
bly. There are six transmembrane alpha helical domains that are denoted as S1–S6 in each SK channel subu-
nit. The pore-forming P-loop between the transmembrane S5 and S6 domains is responsible for the potassium 
ion selectivity. Both the amino- and carboxyl- termini of these channel proteins are on the intracellular side of 
the plasma membrane. In the proximal carboxyl-terminus of the channels, there is a region called calmodulin 
binding domain (CaMBD). The Ca2+ binding protein calmodulin (CaM) that is constitutively associated at the 
CaMBD serves as the Ca2+ sensor of SK channels3. In response to physiological signals, elevated intracellular 
Ca2+ levels enable Ca2+ binding to CaM, inducing conformational changes in the channel carboxyl- terminus and 
subsequently opening the channel pore4–6. As such SK channels are not voltage-dependent but instead rely solely 
on the Ca2+/CaM mediated mechanism described above for their gating. SK channels are therefore often located 
in close proximity to Ca2+ conducting channels or intracellular Ca2+ sources1,2.
SK channels play essential roles in the regulation of membrane excitability by Ca2+ in both the central nervous 
and cardiovascular systems1,2. In the cardiovascular system, SK channels in the heart have been shown to con-
tribute to the regulation of the cardiac action potential7–11 while SK channels in the endothelium are implicated 
in the regulation of vascular tone12–15. In the central nervous system, activation of SK channels generates the 
medium afterhyperpolarization (mAHP) and reduces the firing frequency of action potentials, thus contributing 
to the regulation of neuronal excitability1,16. In neurons, SK channels are subject to regulation by posttransla-
tional modification; e.g., phosphorylation. Ca2+ sensitivity of SK channels is reduced by phosphorylation of a 
specific threonine residue (Thr79) in CaM. The phosphorylation status of CaM Thr79, and thus Ca2+ sensitivity 
of the channels, is regulated by an interplay between casein kinase 2 and protein phosphatase 2A2,17. For example, 
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neurotransmitters such as acetylcholine18 and norepinephrine19 can induce changes in the phosphorylation status 
of CaM Thr79, and thus regulate the Ca2+ sensitivity of SK channels and neuronal excitability.
The pharmacology of the SK channels is relatively well developed. Apamin, previously considered a blocker, 
actually acts on the SK channel outer pore through an allosteric mechanism20,21. TRAM-34 in contrast is a potent 
inner pore blocker of the IK channel22,23, while UCL-1684 and its analogs bind to the outer vestibule of the SK 
channels24. Negative modulation of SK1-3 channel subtypes can be achieved by NS8593, a compound that appar-
ently reduces the Ca2+ sensitivity of the channels25,26. Interestingly, the negative gating modulator BU-TRMF 
exhibits selectivity of the SK1 channel27, whereas RA-2 is a negative modulator for SK3 and IK channel subtypes28. 
On the other hand, positive modulators of SK channels such as 1-ethyl-2-benzimidazolinone (1-EBIO)29 and 
NS30930 can potentiate SK channel activity.
Given the essential roles of SK channels in the cardiovascular system and the central nervous system, SK 
channels have been proposed as drug targets for the treatment of hypertension31–35 and movement disorders36–41. 
Purkinje cells in the cerebellum are the primary locus of pathology in spinocerebellar ataxia42,43. SK channel pos-
itive modulators have been demonstrated to normalize firing rates of cerebellar Purkinje cells through SK2 chan-
nel activation and to exert beneficial effects in mouse models of ataxia40,44,45. Accordingly a significant amount 
of effort has been devoted to developing small molecules that target SK channels46. The prototype 1-EBIO was 
identified almost two decades ago as a positive modulator29. 1-EBIO increases the Ca2+ sensitivity of SK channels, 
which enhances the mAHP and effectively modulates neuronal excitability47. A Scandinavian biopharmaceutical 
company (NeuroSearch A/S) has developed additional compounds, including NS30930.
Despite all this progress, it remained unknown where on the SK channels these positive modulators bind, 
until our previous publications48,49. We first discovered the binding site of 1-EBIO at the CaM-channel interface. 
This was done using a combination of approaches, including x-ray crystallography, computational biology and 
electrophysiology. In the crystal structure (PDB Code: 4G28), 1-EBIO bound at the interface of CaMBD and the 
CaM N-lobe, forming close contacts with both CaM and CaMBD. Later we found that the more potent SK chan-
nel positive modulator NS309 also binds into the same binding pocket as 1-EBIO (PDB Code: 4J9Z).
Here we describe a trend between the interaction energy (Eint) of the compounds within their binding site cal-
culated from the crystal structures, and the potency (EC50) of these compounds in potentiating the SK2 channel 
current determined by electrophysiological recordings. This was done utilizing four compounds,1-EBIO, NS309, 
SKS-11 (6-bromo-5-methyl-1H-indole-2,3-dione-3-oxime) and SKS-14 (7-fluoro-3-(hydroxyimino)indolin-
2-one), varying up to 1000-fold in potency. We investigated the activity of the compounds through electrophys-
iology and the binding modes by determining x-ray crystal structures of the modulators bound within their 
binding pocket. Further analysis of the crystal structures show that the strength of electrostatic interactions may 
be the primary reason why some compounds are more potent than others. Our results provide structural insights 
into how the potency of SK channel modulators can be improved and thus may facilitate the future development 
of more potent modulators.
Results and Discussion
The potency of SK channel positive modulators. Previously we discovered a binding pocket in the 
SK2 channel shared by two positive modulators 1-EBIO and NS30948,49. In this study, we utilized the crystal 
structure of the NS309 molecule in complex with its SK2 binding pocket (PDB code: 4J9Z) for computer based 
virtual screening. The Glide module in Maestro50 was used for virtual screening of the Specs library (www.specs.
net), which yielded a list of 30 hit compounds. These compounds were purchased and their effects on the SK2 
current were tested using inside-out patch-clamp recordings as previous described48,49,51. Positive modulators of 
SK channels like 1-EBIO and NS309 (Fig. 1a) increase the SK channel activity at Ca2+ concentrations below the 
EC50 for Ca2+ activation of these channels16,30. The EC50 for the activation of SK2-a channel by Ca2+ is ~0.32 μM 
in our previous report6. Therefore we tested these compounds up to the concentration of 1 mM in the presence 
of 0.1 μM Ca2+. Two compounds (SKS-11 and SKS-14, Fig. 1a) potentiated the SK2 current (Figs 1b and c). The 
other 28 compounds did not induce any change in the SK2 current. The chemical structures and Specs ID (www.
specs.net) are shown in Supplementary Fig. S1.
The two positive modulators SKS-11 and SKS-14 closely resemble 1-EBIO and NS309 in their chemical struc-
tures (Fig. 1a). Similar to 1-EBIO and NS309, both SKS-11 and SKS-14 dose-dependently potentiated SK2 chan-
nel activity at 0.1 μM Ca2+ (Figs 1b and c). These two positive modulators demonstrated similar efficacy compared 
to 1-EBIO and NS309 in potentiation of SK2 channels (Supplementary Fig. S2). The maximal responses to the 
modulators were normalized by the SK2 currents induced by the saturating Ca2+ concentration of 10 μM. The 
normalized maximal responses to NS309, SKS-11, SKS-14 and 1-EBIO were 93.02 ± 2.85% (n = 8), 94.60 ± 3.03% 
(n = 8), 92.03 ± 3.44% (n = 9) and 96.17 ± 4.20% (n = 6) of the currents induced by 10 μM Ca2+, respectively 
(Supplementary Fig. S2). There is no significant difference between the normalized maximal responses of these 
compounds.
On the other hand, these four modulators differed in their potency (EC50 values) from each other 
(Supplementary Fig. S2). The concentration-response curves of these modulators are shown in Fig. 1d. The 
EC50 values of NS309, SKS-11, SKS-14 and 1-EBIO for potentiating SK2 current are 0.552 ± 0.083 μM (n = 8), 
3.87 ± 0.88 μM (n = 8), 33.2 ± 4.8 μM (n = 9) and 286 ± 31 μM (n = 6) respectively. NS309 is about 500-fold more 
potent than 1-EBIO. The potency of SKS-11 and SKS-14 falls between 1-EBIO and NS309. To confirm that the 
currents that we measured indeed came from the SK2 channel, we utilized apamin. Apamin (20 nM) almost com-
pletely abolished the current measured in control experiments (Supplementary Fig. S3).
A moiety shared by the four active compounds is a benzene ring fused with a heterocyclic five-member ring 
containing at least one nitrogen atom (Fig. 1a). The substituents on the benzene ring include electron withdraw-
ing halogen groups (chloro, bromo and fluoro) and an electron donating methyl group. Fluoro substitution at 
position 7 (SKS-14), bromo substitution at position 6 (SKS-11) or chloro groups at both position 6 and 7 (NS309) 
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might direct the distribution of electron density from the neighboring heterocyclic ring. It seems that the com-
pounds with halogen groups at the position 6 and 7 are more potent in potentiating the SK2 channel than com-
pounds lacking halogen substituents in these positions (Fig. 1d).
The shared binding pocket of SK channel positive modulators. We performed virtual screening 
hoping to discover new scaffolds different from NS309 and 1-EBIO. However, we were only able to identify 
two active compounds, SKS-11 and SKS-14, which both closely resemble 1-EBIO and NS309 in their chemical 
structure (Fig. 1a). In future studies, the model needs to be parameterized and trained better to allow for the 
identification of new scaffolds different from NS309 and 1-EBIO. One possible approach is to utilize multiple 
conformations of the binding pocket generated from Molecular Dynamics simulations for virtual screening to 
discover new scaffolds.
The identification of SKS-11 and SKS-14 that closely resemble 1-EBIO and NS309 in structure, however, offers 
us an opportunity to correlate structure and activity at the atomistic level. To address this question, we first sought 
to determine the crystal structures of SKS-11 and SKS-14 in complex with their binding pocket (PDB codes, 
5WBX and 5WC5). Reminiscent of the binding pockets of 1-EBIO and NS30948,49, the binding site for SKS-11 
and SKS-14 is also located at the interface of CaMBD and the CaM N-lobe (Fig. 2a and b). At the CaM-channel 
interface, between M51, M71, K75 of CaM and L480 of CaMBD, there is extra electron density apparently coming 
from SKS-11 and SKS-14, respectively. Overlaid conformations of compounds obtained from their respective 
protein complex structure show subtle but clear differences, especially for 1-EBIO (Fig. 2c and d). Nonetheless, 
these crystal structures demonstrate that NS309, SKS-11, SKS-14 and 1-EBIO all bind to a shared binding pocket 
at the CaM-channel interface.
The interaction energy of modulators within the binding pocket. After obtaining crystal struc-
tures (Fig. 2) of the binding pocket in complex with compounds of different potency (Fig. 1d and Supplementary 
Fig. S2), we next explored the interactions between the binding pocket and the compounds and correlated them 
to the compound potency.
NS309, SKS-11, SKS-14 and 1-EBIO all primarily form contacts with L480 of the CaMBD and with M51, M71 
and K75 of CaM. Motivated by the different conformations of the compounds in the binding pocket (Fig. 2), 
we calculated the interaction energy (Eint) between the compounds and the binding pocket from the crystal 
structures using Discovery Studio 3.5 molecular modeling program (Accelrys Software Inc.). The total Eint is 
−43.5 kcal/mol for NS309, −38.8 kcal/mol for SKS-11, −32.6 kcal/mol for SKS-14 and −29.5 kcal/mol for 1-EBIO 
(Fig. 3a). The total Eint, calculated from the structures of the compound-bound complexes correlates extremely 
well with the potency (EC50) of the compounds (r = 0.99, Fig. 3b).
In the Discovery Studio 3.5 molecular modeling program, which is using the CHARMM force field, the total 
interaction energy is defined as the sum of the Van der Waals force (VDW, e.g. repulsion or attraction between 
atoms) and electrostatic interactions (e.g. interactions due to distribution of the electrons including hydrogen 
bonds) (Fig. 3a). The interface between CaM and its target protein is relatively hydrophobic4,6,52. It is therefore 
not surprising that the VDW Eint contributes to a big portion of the total Eint between these compounds and their 
largely hydrophobic binding pocket. The VDW Eint is −31.2 kcal/mol for NS309, −30.9 kcal/mol for SKS-11, 
−25.1 kcal/mol for SKS-14 and −27.6 kcal/mol for 1-EBIO (Fig. 3a). On the other hand, the electrostatic Eint is 
−12.3 kcal/mol for NS309, −7.9 kcal/mol for SKS-11, −7.5 kcal/mol for SKS-14 and −1.8 kcal/mol for 1-EBIO 
Figure 1. SK channel positive modulators. (a) The chemical structures of NS309, 1-EBIO, SKS-11 and SKS-14. 
(b) Raw current traces of dose-dependent channel potentiation by SKS-11 in the presence of 0.1 μM Ca2+. (c)  
Raw current traces of dose-dependent channel potentiation by SKS-14 in the presence of 0.1 μM Ca2+. (d) Dose-
dependent potentiation of the SK2 current by NS309, SKS-11, SKS-14 and 1-EBIO, respectively. All data are 
presented in mean ± s.e.m.
www.nature.com/scientificreports/
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(Fig. 3a). The potency of the four compounds is much better correlated with the electrostatic Eint (r = 0.91, Fig. 3c) 
than the VDW Eint (r = 0.74, Fig. 3d). As such, even though the VDW Eint contributes a bigger portion to the total 
Eint, the electrostatic Eint is actually the primary reason why these compounds exhibit potency differences.
The electrostatic interactions of modulators within the binding pocket. Due to the importance 
of the electrostatic Eint for the potency differences of the four compounds, we examined the amino acid residues 
within the binding pocket that form electrostatic interactions with the compounds, namely M51 and K75 from 
CaM together with A477 from the CaMBD. The oxygen and nitrogen atoms in NS309 (Fig. 4a), SKS-11 (Fig. 4b), 
SKS-14 (Fig. 4c) and 1-EBIO (Fig. 4d) that form electrostatic interactions are connected by dashed lines with 
these three residues in the crystal structures. Generally, the distance from these residues is shorter for the more 
potent compounds (NS309 < SKS-11 < SKS-14 < 1-EBIO, Fig. 4e).
For instance, the distance and angles (θ) from the main chain oxygen of M51 to the nitrogen in the 
five-member heterocyclic ring is 2.8 angstrom (θ = 134.7°) for NS309, 2.9 angstrom (θ = 164.2°) for SKS-11, 3.1 
angstrom (θ = 129.7°) for SKS-14 and 4.1 angstrom (θ = 120.6°) for 1-EBIO. The distance from the main chain 
oxygen of A477 to the nitrogen in the “ = N-OH” group is 3.6 angstrom (θ = 129.9°) for NS309, 4.0 angstrom 
(θ = 105.2°) for SKS-11 and 4.9 angstrom (θ = 92.8°) for SKS-14. There is no the “=N-OH” group in 1-EBIO 
(Fig. 1a). The main chain oxygen of A477 may interact weakly with the other nitrogen in the five-member ring 
with a distance of 4.6 angstrom (θ = 90.9°). The distance from the side chain nitrogen (Nζ) of K75 to the oxygen in 
the “=N-OH” group is 2.7 angstrom (θ = 93.3°) for NS309, 3.0 angstrom (θ = 135.8°) for SKS-11 and 2.7 angstrom 
(θ = 102.7°) for SKS-14. 1-EBIO that lacks the “=N-OH” group, may undergo a weak interaction with the side 
chain nitrogen of K75 through its “=O” group with a distance of 5.3 angstrom.
As electrostatic Eint (e.g. hydrogen bond) is closely related to the length and angle of the interaction, we further 
examined the electrostatic Eint between the compounds and the three residues. Consistent with our findings from 
the crystal structures (Fig. 4), M51 and K75 of CaM together with A477 of the CaMBD are the residues that form 
electrostatic interactions stronger than −1 kcal/mol with the compounds. The electrostatic Eint with the M51 is 
Figure 2. Shared binding site of the SK channel positive modulators. (a) Electron density map (grey, |Fo|-|Fc|) 
showing the presence of additional electron density at the interface between CaM (cyan) and the CaMBD 
(salmon). The map is contoured at 3.7 σ and is overlaid with the current refined coordinates for SKS-11. (b) 
Electron density map (grey) showing the presence of additional electron density. The map is contoured at 3.7 
σ and is overlaid with the current refined coordinates for SKS-14. (c) NS309, SKS-11, SKS-14 and 1-EBIO all 
bind to the interface between the CaM (cyan) N-lobe and the CaMBD (salmon). (d) Overlaid conformations 
of compounds obtained from their respective protein complex crystal structures. The carbon atoms of the 
compounds are shown in pale green (NS309), grey (SKS-11), magenta (SKS-14) and yellow (1-EBIO).
www.nature.com/scientificreports/
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−4.7 kcal/mol for NS309, −2.3 kcal/mol for SKS-11, −1.6 kcal/mol for SKS-14 and −0.5 kcal/mol for 1-EBIO 
(Fig. 5a). The electrostatic Eint with the K75 is −4.8 kcal/mol for NS309, −4.9 kcal/mol for SKS-11, −5.9 kcal/
mol for SKS-14 and −0.9 kcal/mol for 1-EBIO (Fig. 5b). The electrostatic Eint with the A477 is −2.9 kcal/mol for 
NS309, −0.3 kcal/mol for SKS-11, −0.7 kcal/mol for SKS-14 and −0.01 kcal/mol for 1-EBIO (Fig. 5c). NS309 is 
the only compound that forms electrostatic interactions with all three residues with electrostatic Eint stronger than 
−1 kcal/mol (Fig. 5d), which might explain its high potency in potentiating the SK2 channel (Fig. 1d). Compared 
to the 6-bromo atom of SKS-11 and 7-fluoro atom of SKS-14, the 6,7-chloro atoms on the benzene ring of NS309 
might have enabled optimized the electrostatic interactions between NS309 and the residues of M51, K75 and 
A477.
Electrostatic interactions such as hydrogen bonds are important specific interactions between ligands and the 
protein structures, which are often used to improve the efficacy of small molecule drugs through structure-aided 
drug design53,54. Our results here show that the potency of a series of NS309 analogs correlates extremely well 
with their Eint, suggesting that one strategy to further improve the potency of SK channel modulators could 
be to further increase the strength of electrostatic interactions when searching for novel compounds through 
structure-aided drug design.
Method
Virtual Screening. The crystal structure of the NS309 molecule in complex with its binding pocket in the 
CaM/CaMBD complex from the SK2-a channel (PDB code: 4J9Z) was prepared with the workflow of Protein 
Preparation Wizard implemented in Maestro. Hydrogen atoms were added, followed by optimization of hydro-
gen bonds. Then energy was optimized to refine improper atoms using the OPLS2005 force field. Afterwards, 
the generation of a receptor grid was performed with Glide50 in Maestro. The location of NS309 was used as 
ligand-binding site. A box with a length of 12 angstroms, which surrounded the ligand-binding site, was set for 
grid generating.
The Specs library that contains approximately 200,000 compounds was used as the ligand database (www.
specs.net). These ligands were filtered with Pipeline Pilot (version 7.5)55 in the following successive steps. The 
organic filter and knowledge-based HTS filter were applied for removing inorganic, undesirable and potentially 
toxic molecules. Then, the application of the Lipinski’s rule of five56 removed structures unlikely to have drug-like 
properties. Subsequently, PAINS (pan-assay interference compounds)57,58 were removed. The remaining 179,098 
compounds were prepared with LigPrep implemented in Maestro59, generating possible protonation states and 
different stereoisomers using Epik at the target pH of 7.0.
Figure 3. Eint between the compounds and their binding pocket. (a) Stacked column plot showing the total Eint 
that is composed of VDW Eint (grey) and electrostatic Eint (white). (b) The correlation between the total Eint and 
the potency of NS309, SKS-11, SKS-14 and 1-EBIO (r = 0.99). (c) The correlation between the electrostatic Eint 
and the potency of NS309, SKS-11, SKS-14 and 1-EBIO (r = 0.91). (d) The lack of correlation between the VDW 
Eint and the potency of NS309, SKS-11, SKS-14 and 1-EBIO (r = 0.74). In (b,c and d), the y-axis is set in log-10 
scale.
www.nature.com/scientificreports/
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The Glide50 module in Maestro was used for virtual screening. The prepared ligands were docked into the 
binding pocket with the Standard Precision (SP) mode. During the docking process, dock flexible parameters 
were selected. The resulting poses were ranked by their glide docking scores. Meanwhile, the NS309 molecule was 
extracted from the complex structure, prepared, and was docked into the structure with the same parameters, 
scoring -7.780 in SP mode. In the virtual screening, a total of 10,242 poses scored less than -7 were obtained, 
which were subsequently redocked into the structure with Extra Precision (XP) mode. The top-ranked 2000 poses 
were first filtered by removing duplicate molecules. We then clustered the molecules into clusters using finger-
print similarity evaluation in chemical, followed by visual inspection to check the interaction mode for every pose 
in the complex system (small molecule docking with protein), selecting the rational poses from different clusters. 
Finally, 30 compounds were purchased from Specs (www.specs.org) for further testing by electrophysiological 
recordings. Two of them (SKS-11 and SKS-14) potentiated the SK2 current. The remaining 28 compounds did 
not change the SK2 current. The control compounds NS309 and 1-EBIO were purchased from Tocris. Apamin 
was purchased from Alomone Labs.
Electrophysiology
The electrophysiological recordings of SK2 current were performed as described in our previous papers48,49,51. 
Briefly, SK2-a channels, along with CaM and GFP, at a ratio of 5:2.5:1 (weight), were transfected into TsA201 cells 
by the calcium–phosphate method. SK2 currents were recorded 1–2 days after transfection, with an Axon200B 
amplifier (Molecular Devices) at room temperature.
Figure 4. Electrostatic interactions between the compounds and their binding pocket. The amino acid residues 
M51, K75 and A477 within the binding pocket are shown in the crystal structures in complex with (a), NS309 
(PDB code, 4J9Z) (b), SKS-11 (PDB code, 5WBX) (c), SKS-14 (PDB code, 5WC5) (d), 1-EBIO (PDB code, 
4G28), respectively. (e) The distances between the main chain oxygen of M51, the main chain oxygen of A477, 
the side chain nitrogen of K75 and the compounds.
www.nature.com/scientificreports/
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pClamp 10.5 (Molecular Devices) was used for data acquisition and analysis. The resistance of the patch elec-
trodes ranged from 3–5 MΩ. The pipette solution contains (in mM): 140 KCl, 10 Hepes (pH 7.4), 1 MgSO4. The 
bath solution containing (in mM): 140 KCl, 10 Hepes (pH 7.2), 1 EGTA, 0.1 Dibromo-BAPTA, and 1 HEDTA was 
mixed with Ca2+ to obtain the desired free Ca2+ concentrations, calculated using the software by Chris Patton of 
Stanford University (http://www.stanford.edu/~cpatton/maxc.html). The Ca2+ concentrations were verified using 
Fluo-4 and standard Ca2+ buffers (Thermo Fisher Scientific).
Currents were recorded using an inside-out patch configuration. The intracellular face was initially exposed to 
a zero-Ca2+ bath solution, and subsequently to bath solutions with 0.1 μM Ca2+. Currents were recorded by repet-
itive 1-s-voltage ramps from −100 mV to + 100 mV from a holding potential of 0 mV. One minute after switching 
of bath solutions, ten sweeps with a 1-s interval were recorded at a series of concentrations of the compounds 
in the presence of 0.1 μM Ca2+. The maximal SK2 current in response to 10 μM Ca2+ was then recorded before 
the integrity of the patch was examined by switching the bath solution back to the zero-Ca2+ buffer. Data from 
patches, which did not show significant changes in the seal resistance after solution changes, were used for further 
analysis. To construct the dose-dependent potentiation of channel activities, the current amplitudes at −90 mV in 
response to various concentrations of the compound were normalized to that obtained at maximal concentration 
of that compound. The normalized currents were plotted as a function of the concentrations of each compound. 
EC50 values and Hill coefficients were determined by fitting the data points to a standard dose–response curve 
(Y = 100/(1 + (X/EC50)^ −Hill)). All data are presented in mean ± s.e.m. The Student’s t-test was used for data 
comparison.
Protein crystallization and structure determination. The protein complex consisting of CaM and 
the SK2 channel fragment (R395–Q486 from rat SK2-a channel) was purified as described in our previous 
papers48,49,60. Briefly, rat CaM was introduced into the pET28b(+) vector (Novagen) and expressed in Rosetta-2 
E. Coli. cells (Novagen). The CaM protein was purified using a low substitution phenyl sepharose column (GE 
Healthcare). The SK2 channel fragment was also introduced into the pET28b(+) vector (Novagen) and the 
codons have been optimized to improve expression of this His-tagged protein in E. Coli. This His-tagged protein 
was expressed and purified using a Ni-NTA column. The purified SK2 channel fragment was mixed slowly with 
the purified CaM in the presence of Ca2+ to form a complex, followed by purification with a gel filtration column 
(GE Healthcare) pre-equilibrated in a solution with 10 mM Tris-HCl, 50 mM NaCl, and 10 mM CaCl2 (pH 7.5). 
The purified protein complex was concentrated to about 1 mM and then set up for crystallization. Protein crys-
tals of the protein complex were grown in sitting drops by vapour diffusion at 20 °C. The complex (1 mM) was 
Figure 5. Electrostatic Eint between the compounds and amino acid residues in their binding pocket. (a) The 
electrostatic Eint between the compounds and M51. (b) The electrostatic Eint between the compounds and K75. 
(c) The electrostatic Eint between the compounds and A477. (d) NS309 forms strong electrostatic interactions 
with three residues M51, K75 and A477.
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mixed in a 1:1 ratio with the reservoir solution, which consists of 1.5 M Li2SO4, 0.6 M (NH4)2SO4, 0.1 M sodium 
citrate, pH 5.8. Monoclinic crystals usually grew within 3 weeks. These preformed protein crystals were then 
incubated with SK channel modulators at their saturating concentrations for ~1 month (SKS-11) and ~5 months 
(SKS-14), respectively. The soaked protein crystals were flash-cooled in liquid nitrogen for data collection, after 
a brief transfer to a suitable cryoprotectant (25% glycerol with the reservoir solution saturated with SKS-11 or 
SKS-14). X-ray diffraction data were collected from single crystals on the X-ray diffraction system (D8 Venture 
Diffraction System, Bruker AXS Inc.) at our home institute and processed using PROTEUM2 (Bruker AXS Inc.). 
Initial phases were determined by molecular replacement (MR) using PHASER from the CCP4 suite61. Our previ-
ously determined CaM/CaMBD complex structure (4J9Y) was used as a starting model to phase diffraction data. 
Solvent molecules were removed from the starting molecule before rigid body refinement. The crystallographic 
model was further constructed through iterative rounds of manual model-building using Coot62 and crystallo-
graphic refinement using REFMAC61 and PHENIX63. SKS-11 and SKS-14 were modeled respectively in a pocket 
at the CaM-channel interface based on strong electron density in difference Fourier maps and followed by suc-
cessful refinement of the coordinates. The crystallographic statistics for data collection and model refinement are 
summarized in Supplementary Table 1. Structure graphics were created using PyMol (Schrödinger, LLC).
Interaction Energy Calculation. The Discovery Studio 3.5 molecular modeling program (Accelrys Software 
Inc.) was used to conduct energy minimization and calculate the interaction energy between the compound and 
the protein complex. All structures were subjected to energy minimization using Smart Minimizer algorithm (2000 
steps), and Generalized Born (GB) implicit solvent model using the CHARMM force field. Interaction energies 
between the compound and the protein complex were calculated using a distance dependent dielectric constant 
(ε = 2r) implicit solvent model. The decomposed interaction energy contribution of residues to the total interaction 
energy was analyzed to identify the critical interacting amino acid residues in the protein complex.
Data availability. The structure coordinates have been deposited in the Protein Data Bank under accession 
codes 5WBX and 5WC5.
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